Immunotherapy for Acute Lymphoblastic Leukemia: Novel Strategies and Clinical Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 41
Special Issue Editors
Interests: acute lymphoblastic leukemia; immunotherapy; innovative therapies in acute myeloid leukemia
Special Issue Information
Dear Colleagues,
Acute lymphoblastic leukemia (ALL) remains one of the most challenging hematologic malignancies to treat, particularly in the relapsed and refractory setting. Over the past decade, immunotherapy has revolutionized treatment paradigms, offering novel approaches that harness the patient’s own immune system to eradicate leukemic cells. Breakthroughs such as bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and antibody–drug conjugates have transformed outcomes, while ongoing research continues to refine strategies to improve efficacy, durability, and safety. This Special Issue, Immunotherapy for Acute Lymphoblastic Leukemia: Novel Strategies and Clinical Perspectives, aims to highlight advances in preclinical research, translational studies, and clinical applications that are shaping the future of ALL therapy. Contributions will cover innovative therapeutic modalities, mechanisms of resistance, real-world clinical experiences, and perspectives on integrating immunotherapy into standard treatment algorithms.
Dr. Paola Minetto
Dr. Francesco Grimaldi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- CAR T-cell therapy
- bispecific antibodies
- antibody–drug conjugates
- treatment resistance
- clinical perspectives
- clinical trial in ALL
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
